Understanding CLIA certification and how it differs from CAP accreditation and ISO 15189 is essential before a sequencing laboratory moves from research into clinical testing, because these frameworks are commonly spoken of as if they were one thing and they are not. CLIA is a mandatory federal requirement, the legal floor below which no laboratory in the United States may report results used for patient care. CAP accreditation is a voluntary program that, among other things, satisfies CLIA through a mechanism called deemed status while imposing additional, more rigorous requirements. ISO 15189 is an international standard for medical laboratory quality that matters most outside the United States and in specific regulatory contexts. Treating them as interchangeable leads laboratories to misjudge both what they are legally required to have and what their intended clients will actually accept.

This guide distinguishes the three frameworks precisely: what each covers and its legal status, the personnel qualifications each requires, the molecular and sequencing-specific checklist content, the timeline and cost to reach accreditation, what it takes to maintain it, and the international equivalents that matter for laboratories operating outside or beyond the US system. The aim is to let a laboratory choose the right level of accreditation for its intended clinical role, which is the choice the opening distinction is really about. The analytical validation that accreditation assesses is covered in Validating an NGS Assay for Clinical Use.

What Each Framework Covers

The three frameworks differ first in their legal force, and that difference is the one most often misunderstood. CLIA, the Clinical Laboratory Improvement Amendments, is US federal law administered by the Centers for Medicare and Medicaid Services, and it is mandatory: any laboratory that tests human specimens to produce results for the diagnosis, prevention, or treatment of disease must hold the appropriate CLIA certificate, and for a sequencing laboratory that means a certificate covering high-complexity testing. CLIA is the floor, and operating a clinical laboratory without the required certificate is not permitted.

CAP accreditation, from the College of American Pathologists, is voluntary, but it does two things at once. Through an arrangement with the Centers for Medicare and Medicaid Services known as deemed status, CAP accreditation is recognized as meeting CLIA requirements, so an accredited laboratory satisfies CLIA by being CAP-accredited. At the same time, CAP’s requirements are more detailed and more demanding than the CLIA minimum, so CAP accreditation signals a level of rigor above the legal floor. ISO 15189, an international standard for quality and competence in medical laboratories, occupies a third position: it is a voluntary standard used for accreditation primarily outside the United States, and it becomes specifically relevant in the European Union, where it is tied to the regulation of laboratory-developed diagnostics. The relationships among the three are what the comparison below makes precise.

Table 1. The three frameworks are not interchangeable. CLIA is the mandatory legal floor; CAP is a voluntary accreditation that satisfies CLIA and adds rigor; ISO 15189 is the international standard that matters mainly outside the US.

Advanced Lab Management Certificate

The Advanced Lab Management certificate is more than training—it’s a professional advantage.

Gain critical skills and IACET-approved CEUs that make a measurable difference.

Personnel Qualification Requirements

Clinical sequencing is classified as high-complexity testing, which triggers the most stringent personnel requirements under CLIA, and staffing to those requirements is often one of the harder parts of reaching certification. CLIA defines a set of named personnel roles for a high-complexity laboratory, each with its own qualifications: the laboratory director, who bears overall responsibility; the technical supervisor, responsible for the technical and scientific oversight of the testing; the clinical consultant; the general supervisor; and the testing personnel who perform the work. The laboratory director of a high-complexity laboratory must meet demanding qualifications, typically a physician with relevant board certification or a doctoral scientist with appropriate certification and experience, and the role carries responsibilities that cannot be delegated away.

These requirements were recently updated for the first time in decades, which is worth noting because guidance written earlier may be out of date. The Centers for Medicare and Medicaid Services revised the CLIA personnel regulations effective at the end of 2024, adjusting qualification and responsibility details across several roles, so a laboratory should work from the current regulation rather than older summaries. CAP layers its own personnel expectations on top of the CLIA roles, consistent with its higher bar. Getting the required qualified personnel in place, particularly a qualified laboratory director and technical supervisor for high-complexity molecular work, is a prerequisite to confirm early, because it can be a binding constraint on the timeline.

Interested in lab leadership?

Register for a FREE Lab Manager account to subscribe to our Lab Leadership Digest Newsletter.

Subscribe for Free

Molecular and NGS-Specific Checklists

CAP assesses compliance through discipline-specific checklists, and for a sequencing laboratory the relevant ones combine general laboratory requirements with molecular and sequencing-specific content. The checklists that apply to a clinical NGS laboratory include the general requirements that apply to all laboratories, the requirements common across disciplines, and, most specifically, the molecular pathology checklist, which contains the requirements particular to molecular testing and dedicated content for next-generation sequencing. That NGS content addresses the aspects of sequencing that general molecular requirements do not, spanning the specific steps of a sequencing test.

The sequencing-specific requirements track the workflow of a clinical NGS test end to end: library preparation and any barcoding, indexing, and pooling; the sequencing itself and its quality metrics; the bioinformatics analysis, including variant calling and annotation; and the generation of the final patient report. In other words, the checklist requires that each stage, from sample to reported result, be validated, controlled, and documented, which is why the analytical validation of the assay is inseparable from accreditation. A laboratory preparing for CAP accreditation of an NGS test should obtain the current molecular pathology checklist and work through its sequencing requirements specifically, since these are updated as the field evolves and are the concrete standard against which the laboratory will be inspected.

Timeline and Cost to Accreditation

Reaching accreditation takes longer than laboratories expect, and planning the timeline realistically is part of planning the clinical program, because the steps are sequential and several cannot be rushed. Obtaining CLIA certification itself is a defined application and, for high-complexity testing, survey process, but the larger effort is everything that has to be in place before and around it: qualified personnel hired, the quality management system built and operating, every assay validated and documented, procedures written, and staff trained and competency-assessed. For a laboratory adding CAP accreditation, the peer-inspection process adds its own preparation and scheduling. Realistically, moving a laboratory from research operation to accredited clinical testing is measured in many months to more than a year, dominated not by the paperwork of certification but by the substantive work of building and documenting a compliant operation.

The cost follows the same pattern, concentrated less in the certification and accreditation fees themselves than in what compliance requires: qualified personnel, whose salaries are ongoing; the validation of each assay, which is substantial skilled work; the quality systems and documentation; and the proficiency testing and ongoing quality control that accreditation demands. A laboratory should budget for accreditation as a program with a significant setup cost and a continuing operating cost, not as a one-time fee, and should sequence the work so that the long-lead items, personnel and validation above all, are started early. How this fits the broader move from research to regulated testing is developed in Quality and Compliance in NGS Labs: From Research Use to Regulated Testing.

Maintaining Accreditation

Accreditation is not a one-time achievement but a state that must be continuously maintained, and a laboratory that treats it as a certificate to be earned once will fail its next inspection. Maintenance has a defined rhythm: CAP-accredited laboratories are inspected on-site every two years and perform a self-inspection in the intervening year, so the laboratory is always either being inspected or preparing to be. Between inspections, the requirements that were demonstrated at accreditation, the quality management system, the validated assays, the competency of personnel, the proficiency testing, must be kept operating and documented continuously, because compliance is assessed as an ongoing condition, not a snapshot.

The practical implication is that accreditation imposes a permanent operating discipline: continuous quality management, ongoing competency assessment, participation in proficiency testing, and the documentation that demonstrates all of it, sustained indefinitely. Revalidation obligations add to this whenever an assay changes, and the ongoing external quality assessment that accreditation requires is a subject in its own right, developed in Proficiency Testing and External Quality Assessment for Sequencing Labs. A laboratory that builds these habits into its routine operation maintains accreditation as a byproduct of running well; one that treats each inspection as a special event to prepare for lurches from crisis to crisis and risks findings that a steady operation would never incur.

International Equivalents

Outside the United States, the accreditation landscape is different, and the standard that matters most is ISO 15189, the international standard for quality and competence in medical laboratories, against which clinical laboratories in much of the world are accredited by their national accreditation bodies. Its current version, ISO 15189:2022, is the reference framework a laboratory operating outside the US system will most often work to, and it plays a role analogous to CLIA and CAP combined, defining both quality-system and technical-competence requirements, though the specific legal and administrative context varies by country.

In the European Union, ISO 15189 connects to the regulation of diagnostics through the in vitro diagnostic medical devices regulation, Regulation (EU) 2017/746, known as the IVDR, which governs diagnostic devices including many tests that laboratories develop and run in-house. The IVDR sets requirements for such laboratory-developed tests, including that the laboratory operate a quality management system consistent with ISO 15189, and it is being phased in over an extended transition. As of 2026, following an amendment that extended the original deadlines, the transition timelines for legacy devices run in stages, with the latest phases extending toward the end of the decade, but these deadlines have been amended more than once, so a laboratory in or serving the EU should verify the current dates and its specific obligations rather than relying on any single stated timeline, including this one. A laboratory serving both US and non-US clients may need to satisfy more than one framework at once, which is a matter of mapping the overlapping requirements rather than choosing between them. How accreditation fits the whole quality and operational picture is in Next-Generation Sequencing in the Lab: A Manager’s Guide to Building, Budgeting, and Scaling NGS Capacity.

References and Guidance

The regulations, accreditation programs, and standards referenced in this article. Regulatory timelines, particularly the IVDR transition deadlines, are stated as of 2026 and should be reverified against the issuing bodies, as they have been amended more than once.

Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 CFR Part 493. US Centers for Medicare & Medicaid Services. Personnel requirements for high-complexity testing at Subpart M (e.g., § 493.1443 laboratory director; § 493.1449 technical supervisor; § 493.1461 general supervisor). Personnel regulations revised effective December 28, 2024.

College of American Pathologists. Laboratory Accreditation Program checklists, including the Laboratory General, All Common, and Molecular Pathology checklists (the last containing next-generation sequencing requirements). CAP, 2025 edition. Updated annually.

International Organization for Standardization. ISO 15189:2022, Medical laboratories: requirements for quality and competence. ISO, 2022. (Replaces ISO 15189:2012.)

Regulation (EU) 2017/746 of the European Parliament and of the Council on in vitro diagnostic medical devices (IVDR), as amended by Regulation (EU) 2024/1860 (published 9 July 2024), which extended legacy-device transition deadlines in stages (Class D to 31 December 2027; Class C to 31 December 2028; Class B and Class A-sterile to 31 December 2029). Deadlines as of 2026; verify current dates.

This article was produced under Lab Manager's AI Editorial Guidelines.